comparemela.com

Latest Breaking News On - Douglase onsi - Page 5 : comparemela.com

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported.

United kingdomMatthew deyoungJason baumNovarock biotherapeuticsDouglase onsiSociety for immunotherapy of cancerDrug administrationHead of translational researchLeap therapeutics incPrnewswire leap therapeutics incFlame biosciencesChief scientific officerChief executive officerExclusive optionLicense agreementChief scientific

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

United kingdomMatthew deyoungDouglase onsiPrnewswire leap therapeutics incDrug administrationLeap therapeutics incDistinguish trialExclusive optionLicense agreementChief executive officerFlame biosciencesLeap therapeuticsNasdaq globalAnnual report

Leap Therapeutics (LPTX) Acquires Flame Biosciences

Leap Therapeutics (LPTX) Acquires Flame Biosciences
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPatricia martinDouglase onsiRaymond jamesChristian richardNovarock biotherapeuticsDrug administrationExchange commissionT rowe price associates incHead of public research samsara biocapitalLeap therapeutics incFlame biosciences incFlame biosciencesCo chief executive officerPublic researchRock springs capital

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced.

United kingdomUnited statesNew zealandSouth koreaRepublic of koreaMatthew deyoungDouglase onsiSamuel klempnerSamuelj klempnerCynthia sirardMichael haasHospital cancer centerBeigene ltdHarvard medical schoolProfessor at harvard medical schoolPrnewswire leap therapeutics inc

Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United kingdomNew zealandMatthew deyoungDouglase onsiCynthia sirardSecurities exchangeBeigene ltdLeap therapeutics incLeap therapeuticsChief medical officerSecurities actSecurities exchange actPrivate securities litigation reform actLeap therapeuticAnnual reportQuarterly reports

vimarsana © 2020. All Rights Reserved.